CSL CEO Paul Perreault discusses emerging trends at key JP Morgan Healthcare Conference
By Anthony Farina
January 14, 2016
CSL CEO and Managing Director Paul Perrreault provided his unique perspective on trends in the treatment of serious and rare diseases this week at the influential JP Morgan Healthcare Conference in San Francisco.
According to Perreault, there is an increasing trend toward the use of recombinant therapies in developed markets. He cited several new recombinants for the treatment of bleeding disorders that are currently in development, and which are designed for greater molecular stability and extended half-life. “This is good news for hemophilia patients who dose several times a week,” he said, “and whose dosing intervals may now be extended, providing a transformative change to patients’ lifestyles.”
He cautioned, however, that the healthcare community still has a long way to go in effectively treating patients with bleeding disorders, 75% of whom are either undertreated or not treated at all. Perreault also noted that intravenous immunoglobulins continue to dominate the market in treating immune deficiencies, as well as other conditions in markets around the world.
“As CSL looks to the future, not only will we evaluate novel delivery devices and seek approvals for new indications, but we will pursue new therapeutic areas and develop new formulations,” he said. Perreault concluded by saying that as CSL approaches its 100th anniversary this spring, “The promise we made 100 years ago to save lives and protect the health of people with serious and chronic medical conditions has never been stronger.”
Anthony Farina is CSL’s Vice President of Corporate Affairs and Communications